The effect of selective serotonin reuptake inhibitors on cognitive function in patients with Alzheimer’s disease and vascular dementia: focusing on fluoxetine with long follow-up periods

作者：Yi Xie, Peipei Liu, Yajun Lian, Hongbo Liu, Jian‐Sheng Kang · 发表于：Signal Transduction and Targeted Therapy · 年份：2019 · DOI：10.1038/s41392-019-0064-7 · 被引用次数：47 · 研究领域：Dementia and Cognitive Impairment Research、Neurological Disorders and Treatments、Neurological Disease Mechanisms and Treatments

Alzheimer’s disease (AD) and vascular dementia (VaD) are two of the most common forms of dementia, resulting in increased disability and mortality, impaired quality of life, and serious burdens on society and caregivers. However, the presently available drugs can only alleviate symptoms for a short time without delaying the progression of the cognitive disorders. Since 2003, no new drugs have been approved by the US Food and Drug Administration for the treatment of AD. In 2019, phase III clinical trials of crenezumab and aducanumab, two anti-amyloid beta monoclonal antibodies, were terminated. The scant progress in clinical trials urges efforts towards an alternative therapeutic strategy for dementia.